Comparative Cardiovascular Efficacy of SGLT2 Inhibitors, DPP-4 Inhibitors, and GLP-1 Agonists-A Network Meta-analysis

被引：0
|
作者：
Roddick, Alistair J.
Zheng, Sean
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-427-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] SGLT-2 inhibitors were not linked to severe or nonsevere UTIs vs DPP-4 inhibitors or GLP-1 agonists
    Davidson, Mayer B.
    ANNALS OF INTERNAL MEDICINE, 2019, 171 (12) : JC70 - JC70
  • [22] Global View on Safety and Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors
    Timofte, L.
    Stratmann, B.
    Bojita, M. T.
    Quester, W.
    Tschoepe, D.
    DIABETES STOFFWECHSEL UND HERZ, 2015, 24 (01): : 19 - 27
  • [23] Efficacy of DPP-4 inhibitors, GLP-1 analogues, and SGLT2 inhibitors as add-ons to metformin monotherapy in T2DM patients: a model-based meta-analysis
    Inoue, Hiroyuki
    Tamaki, Yoko
    Kashihara, Yushi
    Muraki, Shota
    Kakara, Makoto
    Hirota, Takeshi
    Ieiri, Ichiro
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (02) : 393 - 402
  • [24] Comparison of SGLT-2 inhibitors, GLP-1 agonist and DPP-4 inhibitors for mortality outcomes in participants with type 2 diabetes: a network meta-analysis of 96 studies
    Zheng, S. L.
    Roddick, A. J.
    EUROPEAN HEART JOURNAL, 2018, 39 : 490 - 491
  • [25] Risk of lower limb amputation in diabetic patients using SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists: a meta-analysis of 2 million patients
    Lu, Yang
    Guo, Caiyun
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2023, 14
  • [26] Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
    Castellana, Marco
    Cignarelli, Angelo
    Brescia, Francesco
    Perrini, Sebastio
    Natalicchio, Annalisa
    Laviola, Luigi
    Giorgino, Francesco
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [27] Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
    Marco Castellana
    Angelo Cignarelli
    Francesco Brescia
    Sebastio Perrini
    Annalisa Natalicchio
    Luigi Laviola
    Francesco Giorgino
    Scientific Reports, 9
  • [28] Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases
    Xie, Yan
    Bowe, Benjamin
    Gibson, Andrew K.
    McGill, Janet B.
    Maddukuri, Geetha
    Yan, Yan
    Al-Aly, Ziyad
    DIABETES CARE, 2020, 43 (11) : 2859 - 2869
  • [29] Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors
    Egan, Aoife M.
    Montori, Victor M.
    ANNALS OF INTERNAL MEDICINE, 2018, 169 (02) : JC2 - JC2
  • [30] GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes
    Ahrén, B
    Schmitz, O
    HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 867 - 876
12345